Anti-KLRC1 Antibody, Non-Fucosylated (BioBet-340ZP) (CAT#: BioBet-340ZP) Datasheet

KLRC1

Killer Cell Lectin Like Receptor C1

Natural killer (NK) cells are lymphocytes that can mediate lysis of certain tumor cells and virus-infected cells without previous activation. They can also regulate specific humoral and cell-mediated immunity. The protein encoded by this gene belongs to the killer cell lectin-like receptor family, also called NKG2 family, which is a group of transmembrane proteins preferentially expressed in NK cells. This family of proteins is characterized by the type II membrane orientation and the presence of a C-type lectin domain. This protein forms a complex with another family member, KLRD1/CD94, and has been implicated in the recognition of the MHC class I HLA-E molecules in NK cells. The genes of NKG2 family members form a killer cell lectin-like receptor gene cluster on chromosome 12. Multiple alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jan 2015]

NKG2; NKG2A; CD159A

Membrane

Diseases associated with KLRC1 include Bare Lymphocyte Syndrome, Type I and Trichohepatoenteric Syndrome 1.

Its related pathways are Immune response Role of DAP12 receptors in NK cells and Hematopoietic Stem Cells and Lineage-specific Markers.

Plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells.

1.Glycosylation at Asn102, Asn103, Asn151, and Asn180 2.Modification sites at PhosphoSitePlus

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4, κ

BioBet-340ZP

Humanized

Human

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to KLRC1. Monalizumab is a humanized monoclonal antibody that can be potentially used in the treatment of Head and neck cancer.

Head and neck cancer

Head and neck cancer